TSI Incorporated, a US developer of precision instruments, has filed a patent infringement lawsuit in the District of Arizona against Azbil BioVigilant. The suit alleges that BioVigilant’s sale of IMD viable detection products constitutes an infringement of TSI’s patent rights.
Minnesota-based TSI has been a leading provider of fluorescence-based viable particle detectors for the homeland defence and military markets in the US for more than 12 years and recently introduced the BioTrak real-time viable particle detector for the monitoring of total and viable particulates in cleanroom manufacturing environments.
Dr Thomas Kennedy, chief executive of TSI, said: “TSI has invested significant resources in developing fluorescence-based particle detection technology and will vigorously defend its IP portfolio.
“We are excited about extending this technology into the pharmaceutical cleanroom environmental monitoring space.”
TSI has exclusively licensed and collaboratively developed fluorescence-based particle detection technology with Canada Defense Research Establishment since the late 1990’s and recently acquired the patent portfolio.
Faegre Baker Daniels is representing TSI.
